S.P.A. Essetifin Acquires 294,115 Shares of Fennec Pharmaceuticals Inc. (FRX) Stock

Fennec Pharmaceuticals Inc. (TSE:FRX) insider S.P.A. Essetifin purchased 294,115 shares of the business’s stock in a transaction dated Tuesday, December 12th. The stock was bought at an average cost of C$8.50 per share, with a total value of C$2,499,977.50.

Fennec Pharmaceuticals Inc. (FRX) opened at C$11.68 on Friday. Fennec Pharmaceuticals Inc. has a one year low of C$2.30 and a one year high of C$16.23.

Separately, Laidlaw assumed coverage on Fennec Pharmaceuticals in a report on Wednesday, November 29th. They issued a “buy” rating and a C$22.00 price target for the company.

ILLEGAL ACTIVITY WARNING: This story was first posted by Community Financial News and is owned by of Community Financial News. If you are viewing this story on another website, it was copied illegally and reposted in violation of U.S. and international copyright law. The original version of this story can be read at https://www.com-unik.info/2017/12/15/s-p-a-essetifin-acquires-294115-shares-of-fennec-pharmaceuticals-inc-frx-stock.html.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, a water soluble thiol compound that acts as a chemical reducing agent, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.

What are top analysts saying about Fennec Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Fennec Pharmaceuticals and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit